Αρχική World News Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC,... World News Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population Από Ogkologos - 20 Οκτωβρίου, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZZ-FIRST study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Indications for Nivolumab 20 Οκτωβρίου, 2020 Approximately 1 Million of New Maternal Orphans Due to Cancer in... 28 Νοεμβρίου, 2022 Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic... 25 Οκτωβρίου, 2024 What Are Multi-Cancer Early Detection Tests and How Might They Impact... 25 Οκτωβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... Take a Small Step Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After...
